FOGPHARMA
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowled... ge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.
FOGPHARMA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.fogpharma.com
Total Employee:
51+
Status:
Active
Contact:
617-945-9510
Total Funding:
184 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Design Pharmaceuticals
Design Pharma has a unique suite of proprietary technologies that enable the discovery and biosynthetic production of drug candidates.
Digbi Health
Digital health company that harnesses gut microbiome & genetic risk signals to reverse inflammatory digestive disorders, diabetes, obesity.
Droplette
Droplette is a needle-free and hand-held device that delivers large molecules deep through skin.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Current Advisors List
Board_member
2018-10-01
Board_member
Current Employees Featured
Greg Verdine Founder, CEO, CSO @ FogPharma
Founder, CEO, CSO
Weiqing Zhou Co-founder & COO @ FogPharma
Co-founder & COO
2015-12-01
Stephen Fair VP of Finance @ FogPharma
VP of Finance
Sandra Smith Vice President and Head of People @ FogPharma
Vice President and Head of People
Keith Orford Chief Medical Officer & EVP of Clinical and Translational Science @ FogPharma
Chief Medical Officer & EVP of Clinical and Translational Science
2021-11-01
Martin Tremblay Vice President of Chemistry @ FogPharma
Vice President of Chemistry
Theodore Martinot VP of Pharmaceutical Development @ FogPharma
VP of Pharmaceutical Development
2021-09-01
Fang Wang Vice President of Biology @ FogPharma
Vice President of Biology
Lihua Yu Chief Data Officer @ FogPharma
Chief Data Officer
2021-08-01
Howard Stern Chief Scientific Officer @ FogPharma
Chief Scientific Officer
Founder
Investors List
Farallon Capital Management
Farallon Capital Management investment in Series C - FogPharma
Invus
Invus investment in Series C - FogPharma
6 Dimensions Capital
6 Dimensions Capital investment in Series C - FogPharma
Casdin Capital
Casdin Capital investment in Series C - FogPharma
Blue Pool Capital
Blue Pool Capital investment in Series C - FogPharma
GV
GV investment in Series C - FogPharma
Deerfield
Deerfield investment in Series C - FogPharma
T. Rowe Price
T. Rowe Price investment in Series C - FogPharma
venBio Partners
venBio Partners investment in Series C - FogPharma
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - FogPharma
Official Site Inspections
http://www.fogpharma.com Semrush global rank: 5.08 M Semrush visits lastest month: 1.62 K
- Host name: 255.11.72.34.bc.googleusercontent.com
- IP address: 34.72.11.255
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "FogPharma"
FogPharma - Crunchbase Company Profile & Funding
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins …See details»
Fog Pharma Company Profile | Management and Employees List
SQL International Organization for Standardization . Python Python Software Foundation . Other Communication and Collaboration Software (5 Technologies) ... John@fogpharma.com: 6: …See details»
FogPharma Company Profile 2024: Valuation, Funding & Investors
Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, and Marshall Wace are 5 of 32 investors who have invested in FogPharma. Who are FogPharma’s competitors? …See details»
FogPharma Company Profile - Office Locations, Competitors
FogPharma has 5 employees at their 1 location and $277.79 m in total funding,. See insights on FogPharma including office locations, competitors, revenue, financials, executives, …See details»
Parabilis Medicines™ – Formerly FogPharma – Announces New …
Oct 28, 2024 About Parabilis Medicines (Formerly FogPharma) Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for …See details»
FogPharma Overview | SignalHire Company Profile
FogPharma is a private company that has been in the industry for 9 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the President & CEO is …See details»
Parabilis Medicines™ – Formerly FogPharma - Yahoo Finance
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform Business Wire Mon, Oct 28, 2024, 7:00 AM 3 min readSee details»
FogPharma - Funding, Financials, Valuation & Investors
FogPharma is funded by 32 investors. venBio Partners and RA Capital Management are the most recent investors. FogPharma has a post-money valuation in the range of $1B to $10B as of …See details»
Parabilis Medicines - Drug pipelines, Patents, Clinical trials - Synapse
May 3, 2023 FogPharma is renaming itself as Parabilis Medicines, announcing a new corporate identity Monday that reflects the imprint left by CEO Mathai Mammen since joining in 2023. ...See details»
FogPharma - VentureRadar
FogPharma was born from the scientific and entrepreneurial vision of founder Dr. Gregory Verdine, a pioneer in the discovery and development of new drug classes that "drug the …See details»
Fog Pharma - News, Locations, Executives and Competitors
Mar 3, 2024 Usearch discovered 1 location for Fog Pharma including locations in Cambridge · Massachusetts. Fog Pharma is headquartered in 30 Acorn Park Dr. Usearch has identified 4 …See details»
FogPharma - Contacts, Employees, Board Members, Advisors
Organization. FogPharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... FogPharma has 10 current employee profiles, including …See details»
Fog Pharmaceuticals - Company Profile - Tracxn
Dec 15, 2024 FogPharma, ARTBIO Partner to Develop Helicon-Enabled ARTs (HEARTs)Contract Pharma • May 14, 2024 • Fog Pharmaceuticals, ARTBIO FogPharma …See details»
FogPharma - Products, Competitors, Financials, Employees, …
FogPharma is a clinical-stage company pioneering a new class of drugs within the pharmaceutical industry. The company's main focus is on developing Helicon therapeutics, which aim to …See details»
Fog clears to reveal Parabilis, a rebranded cancer biotech with big ...
Oct 28, 2024 Having been founded by Greg Verdine, Ph.D>, in 2015, FogPharma became a Fierce 15 winner in 2023 and closed a $145 million financing round in 2024. Amid the …See details»
Greg Miller, MPH, MBA – FogPharma
Greg Miller has spent the last two decades enabling therapeutics companies to reach their potential through financings and establishing strategic partnerships. Greg was most recently …See details»
FogPharma Announces $145 Million Financing to Support …
CAMBRIDGE, Mass., March 01, 2024--FogPharma today announced the successful closing of a $145 million Series E financing round. ... according to the World Health Organization. Despite …See details»
Fog Pharmaceuticals - Work in biotech
The polypeptides designed by FogPharma have an alpha helical shape, which confers unique drug-like properties and greater stability. FogPharma evaluates thousands of new peptides …See details»
FogPharma - Tech Stack, Apps, Patents & Trademarks - Crunchbase
The intellectual property of FogPharma includes 11 registered patents primarily in the ' Organic Chemistry ' category, according to IPqwery. Additionally, FogPharma has registered 7 …See details»
FogPharma Announces $145 Million Financing to ... - Pharma …
Mar 5, 2024 FogPharma, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its …See details»